Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 24091814)

1.

Safety biomarkers in preclinical development: translational potential.

Sasseville VG, Mansfield KG, Brees DJ.

Vet Pathol. 2014 Jan;51(1):281-91. doi: 10.1177/0300985813505117. Epub 2013 Oct 3. Review.

2.

The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.

Amacher DE.

Toxicol Appl Pharmacol. 2010 May 15;245(1):134-42. doi: 10.1016/j.taap.2010.02.011. Epub 2010 Feb 26. Review.

PMID:
20219512
3.

Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.

Sistare FD, DeGeorge JJ.

Biomark Med. 2011 Aug;5(4):497-514. doi: 10.2217/bmm.11.52. Review.

PMID:
21861671
4.

The current status of biomarkers for predicting toxicity.

Campion S, Aubrecht J, Boekelheide K, Brewster DW, Vaidya VS, Anderson L, Burt D, Dere E, Hwang K, Pacheco S, Saikumar J, Schomaker S, Sigman M, Goodsaid F.

Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1391-408. doi: 10.1517/17425255.2013.827170. Epub 2013 Aug 21. Review.

5.

Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?

Holbrook M, Malik M, Shah RR, Valentin JP.

J Pharmacol Toxicol Methods. 2009 Jan-Feb;59(1):21-8. doi: 10.1016/j.vascn.2008.09.001. Epub 2008 Sep 17.

PMID:
18834945
6.

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.

Roses AD.

Neuropsychopharmacology. 2009 Jan;34(1):6-17. doi: 10.1038/npp.2008.153. Epub 2008 Oct 15. Review.

7.
8.

A multistep validation process of biomarkers for preclinical drug development.

Freeman WM, Bixler GV, Brucklacher RM, Lin CM, Patel KM, VanGuilder HD, LaNoue KF, Kimball SR, Barber AJ, Antonetti DA, Gardner TW, Bronson SK.

Pharmacogenomics J. 2010 Oct;10(5):385-95. doi: 10.1038/tpj.2009.60. Epub 2009 Dec 8.

PMID:
19997081
9.

Qualification of imaging biomarkers for oncology drug development.

Waterton JC, Pylkkanen L.

Eur J Cancer. 2012 Mar;48(4):409-15. doi: 10.1016/j.ejca.2011.11.037. Epub 2012 Jan 5. Review.

PMID:
22226478
10.

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, de Bono JS.

Drug Discov Today. 2010 Feb;15(3-4):88-97. doi: 10.1016/j.drudis.2009.11.006. Epub 2009 Dec 2. Review.

PMID:
19961955
11.

Biomarkers for smoking cessation.

Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, David SP, Stein EA, Uhl GR, Conti DV, Green C, Amur S.

Clin Pharmacol Ther. 2013 Jun;93(6):526-38. doi: 10.1038/clpt.2013.57. Epub 2013 Mar 18. Review.

12.

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P.

Cancer J. 2009 Sep-Oct;15(5):406-20. doi: 10.1097/PPO.0b013e3181bd0445. Review.

PMID:
19826361
13.

Validation of analytic methods for biomarkers used in drug development.

Chau CH, Rixe O, McLeod H, Figg WD.

Clin Cancer Res. 2008 Oct 1;14(19):5967-76. doi: 10.1158/1078-0432.CCR-07-4535. Review.

14.

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

Laverty H, Benson C, Cartwright E, Cross M, Garland C, Hammond T, Holloway C, McMahon N, Milligan J, Park B, Pirmohamed M, Pollard C, Radford J, Roome N, Sager P, Singh S, Suter T, Suter W, Trafford A, Volders P, Wallis R, Weaver R, York M, Valentin J.

Br J Pharmacol. 2011 Jun;163(4):675-93. doi: 10.1111/j.1476-5381.2011.01255.x. Review.

15.

From biomarker strategies to biomarker activities and back.

van Gool AJ, Henry B, Sprengers ED.

Drug Discov Today. 2010 Feb;15(3-4):121-6. doi: 10.1016/j.drudis.2009.11.004. Epub 2009 Nov 18. Review.

PMID:
19931413
16.

Metabolomics and its potential in drug development.

Beyo─člu D, Idle JR.

Biochem Pharmacol. 2013 Jan 1;85(1):12-20. doi: 10.1016/j.bcp.2012.08.013. Epub 2012 Aug 23.

PMID:
22935449
17.

Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation.

Alymani NA, Smith MD, Williams DJ, Petty RD.

Eur J Cancer. 2010 Mar;46(5):869-79. doi: 10.1016/j.ejca.2010.01.001. Review.

PMID:
20138504
18.

Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.

Hornberg JJ, Laursen M, Brenden N, Persson M, Thougaard AV, Toft DB, Mow T.

Drug Discov Today. 2014 Aug;19(8):1131-6. doi: 10.1016/j.drudis.2013.12.008. Epub 2013 Dec 22. Review.

PMID:
24368175
19.

A generic operational strategy to qualify translational safety biomarkers.

Matheis K, Laurie D, Andriamandroso C, Arber N, Badimon L, Benain X, Bendjama K, Clavier I, Colman P, Firat H, Goepfert J, Hall S, Joos T, Kraus S, Kretschmer A, Merz M, Padro T, Planatscher H, Rossi A, Schneiderhan-Marra N, Schuppe-Koistinen I, Thomann P, Vidal JM, Molac B.

Drug Discov Today. 2011 Jul;16(13-14):600-8. doi: 10.1016/j.drudis.2011.04.011. Epub 2011 May 6. Review.

PMID:
21570476
20.

Challenges of biomarkers in drug discovery and development.

Goodsaid F.

Expert Opin Drug Discov. 2012 Jun;7(6):457-61. doi: 10.1517/17460441.2012.679615. Epub 2012 Apr 4.

PMID:
22471322
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk